The Total Neuropathy Score: A Tool for Measuring Chemotherapy-Induced Peripheral Neuropathy

Ellen M. Lavoie Smith

Susan Beck

Jeffrey A. Cohen

measurements, chemotherapy-induced peripheral neuropathy
ONF 2008, 35(1), 96-102. DOI: 10.1188/08.ONF.96-102

Purpose/Objectives: To describe the psychometric properties, clinical significance, and utility of the Total Neuropathy Score (TNS), a composite measurement tool used to assess chemotherapy-induced peripheral neuropathy (CIPN).

Data Sources: Published articles and abstracts and pertinent article references.

Data Synthesis: CIPN has been quantified inadequately because of the lack of an optimal measurement tool. The TNS is the most comprehensive composite tool to have been tested in oncology settings. The tool assesses neuropathy signs and symptoms and incorporates nerve conduction study results but inadequately assesses neuropathy-related pain severity. Seven studies have reported on the TNS's psychometric properties.

Conclusions: Initial but limited evidence supports the TNS's psychometric properties. The tool is too burdensome and inadequately assesses pain severity. Further revision and testing of the tool are recommended.

Implications for Nursing: TNS simplification and further psychometric testing could lead to future use by oncology nurses.

Jump to a section


    Almadrones, L., McGuire, D.B., Walczak, J.R., Florio, C.M., & Tian, C. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncology Nursing Forum, 31(3), 615-623.
    Armstrong, T., Almadrones, L., & Gilbert, M.R. (2005). Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32(2), 305-311.
    Bauknecht, T., Lueck, H.J., Du Bois, A., Meier, W., Moebus, V., Costa, S., et al. (1997). Interim analysis of a randomized trial comparing cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer [Abstract 715]. Proceedings: American Association for Cancer Research Annual Meeting, 38, 107.
    Bril, V. (1999). NIS-LL: The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology, 41(Suppl. 1), 8-13.
    Calhoun, E.A., Welshman, E.E., Chang, C.H., Lurain, J.R., Fishman, D.A., Hunt, T.L., et al. (2003). Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer, 13(6), 741-748.
    Casey, E.B., Jellife, A.M., Le Quesne, P.M., & Millett, Y.L. (1973). Vincristine neuropathy. Clinical and electrophysiological observations. Brain, 96(1), 69-86.
    Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297-1300.
    Cavaletti, G., Jann, S., Pace, A., Plasmati, R., Siciliano, G., Briani, C., et al. (2006). Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 11(2), 135-141.
    Cavaletti, G., Tredici, G., Petruccioli, M.G., Donde, E., Tredici, P., Marmiroli, P., et al. (2001). Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer, 37(18), 2457-2463.
    Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M.A. (2003). Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). Cancer, 98(4), 822-831.
    Chaudhry, V., Cornblath, D.R., Corse, A., Freimer, M., Simmons-O'Brien, E., & Vogelsang, G. (2002). Thalidomide-induced neuropathy. Neurology, 59(12), 1872-1875.
    Chaudhry, V., Eisenberger, M.A., Sinibaldi, V.J., Sheikh, K., Griffin, J.W., & Cornblath, D.R. (1996). A prospective study of suramin-induced peripheral neuropathy. Brain, 119(Pt. 6), 2039-2052.
    Chaudhry, V., Rowinsky, E.K., Sartorius, S.E., Donehower, R.C., & Cornblath, D.R. (1994). Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Annals of Neurology, 35(3), 304-311.
    Cornblath, D.R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total Neuropathy Score: Validation and reliability study. Neurology, 53(8), 1660-1664.
    du Bois, A., Luck, H.J., Bauknecht, T., Mobus, V., Bochtler, H., Diergarten, K., et al. (1997). Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Annals of Oncology, 8(4), 355-361.
    Dyck, P.J., Karnes, J., O'Brien, P.C., & Swanson, C.J. (1986). Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology, 36(10), 1300-1308.
    Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. (1999). Journal of the National Cancer Institute, 91(1), 66-72.
    England, J.D., Gronseth, G.S., Franklin, G., Miller, R.G., Asbury, A.K., Carter, G.T., et al. (2005). Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology, 64(2), 199-207.
    Feldman, E.L., & Stevens, M.J. (1994). Clinical testing in diabetic peripheral neuropathy. Canadian Journal of Neurological Sciences, 21(4), S3-S7.
    Franse, L.V., Valk, G.D., Dekker, J.H., Heine, R.J., & van Eijk, J.T. (2000). "Numbness of the feet" is a poor indicator for polyneuropathy in type 2 diabetic patients. Diabetic Medicine, 17(2), 105-110.
    Galer, B.S. (1995). Neuropathic pain of peripheral origin: Advances in pharmacologic treatment. Neurology, 45(12, Suppl. 9), S17-S25.
    Galer, B.S. (1998). Painful polyneuropathy. Neurologic Clinics, 16(4), 791-812.
    Gregg, R.W., Molepo, J.M., Monpetit, V.J., Mikael, N.Z., Redmond, D., Gadia, M., et al. (1992). Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. Journal of Clinical Oncology, 10(5), 795-803.
    Guiheneuc, P., Ginet, J., Groleau, J.Y., & Rojouan, J. (1980). Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. Journal of the Neurological Sciences, 45(2-3), 355-366.
    Hagiwara, H., & Sunada, Y. (2004). Mechanism of taxane neurotoxicity. Breast Cancer, 11(1), 82-85.
    Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15-49.
    Hilkens, P.H., & ven den Bent, M.J. (1997). Chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2(4), 350-361.
    Hilkens, P.H., Verweij, J., Stoter, G., Vecht, C.J., van Putten, W.L., & ven den Bent, M.J. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology, 46(1), 104-108.
    Kopec, J.A., Land, S.R., Cecchini, R.S., Ganz, P.A., Cella, D., Costantino, J.P., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of Supportive Oncology, 4(8), W1-W7.
    Markman, M. (2006). Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. Current Pain and Headache Reports, 10(4), 275-278.
    Markman, M., Kennedy, A., Webster, K., Kulp, B., Peterson, G., & Belinson, J. (2001). Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. Journal of Cancer Research and Clinical Oncology, 127(1), 55-58.
    Marrs, J., & Newton, S. (2003). Updating your peripheral neuropathy "knowhow." Clinical Journal of Oncology Nursing, 7(3), 299-303.
    Ocean, A.J., & Vahdat, L.T. (2004). Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer, 12(9), 619-625.
    Ostchega, Y., Donohue, M., & Fox, N. (1988). High-dose cisplatin-related peripheral neuropathy. Cancer Nursing, 11(1), 23-32.
    Pestronk, A., Florence, J., Levine, T., Al-Lozi, M.T., Lopate, G., Miller, T., et al. (2004). Sensory exam with a quantitative tuning fork: Rapid, sensitive and predictive of SNAP amplitude. Neurology, 62(3), 461-464.
    Postma, T.J., Aaronson, N.K., Heimans, J.J., Muller, M.J., Hildebrand, J.G., Delattre, J.Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135-1139.
    Postma, T.J., & Heimans, J.J. (1997). Chemotherapy-induced peripheral neuropathy. In P.J. Vecht, G.W. Bruyn, & K.E. Davis (Eds.), Handbook of clinical neurology series. Neuro-oncology: Part III (pp. 459-479). Amsterdam: Elsevier Sciences.
    Postma, T.J., Heimans, J.J., Muller, M.J., Ossenkoppele, G.J., Vermorken, J.B., & Aaronson, N.K. (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 9(7), 739-744.
    Quasthoff, S., & Hartung, H.P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249(1), 9-17.
    Ruppert, M., & Croarkin, E. (2003). A review of four vibration sensation assessments used to examine chemotherapy induced neuropathy. Rehabilitation Oncology, 21(3), 11-18.
    Russell, J.W., Windebank, A.J., McNiven, M.A., Brat, D.J., & Brimijoin, W.S. (1995). Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Research, 676(2), 258-267.
    Screnci, D., & McKeage, M.J. (1999). Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches. Journal of Inorganic Biochemistry, 77(1-2), 105-110.
    Smith, E.L., Whedon, M.B., & Bookbinder, M. (2002). Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing, 18(1), 36-43.
    Stillman, M., & Cata, J.P. (2006). Management of chemotherapy-induced peripheral neuropathy. Current Pain and Headache Reports, 10(4), 279-287.
    Sweeney, C.W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing, 6(3), 163-166.
    Verstappen, C.C., Heimans, J.J., Hoekman, K., & Postma, T.J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63(15), 1549-1563.
    Vileikyte, L., Peyrot, M., Bundy, C., Rubin, R.R., Leventhal, H., Mora, P., et al. (2003). The development and validation of a neuropathy- and foot ulcerspecific quality of life instrument. Diabetes Care, 26(9), 2549-2555.
    Visovsky, C. (2003). Chemotherapy-induced peripheral neuropathy. Cancer Investigation, 21(3), 439-451.
    Wampler, M.A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, L.S. (2006). The modified Total Neuropathy Score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. Journal of Supportive Oncology, 4, W9-W16.